Skip to content
2000
Volume 7, Issue 2
  • ISSN: 2666-7967
  • E-ISSN: 2666-7975

Abstract

Introduction

The spectrum of COVID-19 in adults ranges from asymptomatic infection to mild respiratory tract symptoms to severe pneumonia with acute respiratory distress syndrome (ARDS) and multiorgan dysfunction. In our study, it was aimed to investigate the effects of COVID-19 vaccine on lung involvement and hospitalization.

Materials and Methods

Cases over the age of 18, who had a history of contact with cases infected with COVID-19 or had clinical findings suggestive of COVID-19, who applied to the emergency department and who were diagnosed with COVID-19 by reverse-transcriptase-polymerase chain reaction (RT-PCR) were included in the study. Age, gender, comorbid diseases, hospitalization status, thorax tomography findings, and vaccination status in the last 3 months of the patients included in the study were obtained by examining the hospital information system and patient files.

Results and Discussion

Our study included 496 patients. One hundred eighty-three of the cases were vaccinated and 42.6% (n = 78) of the vaccinated patients were male. Of the 313 unvaccinated patients, 36% (n = 113) were male. Comorbid disease was observed in 55.2% (n = 101) of the vaccinated patients and 38.7% (n = 121) of the unvaccinated patients. Of the 313 unvaccinated patients, 72.2% (n = 226) were discharged from the emergency department, 19.8% (n = 62) were admitted to the service, and 8% (n = 25) were admitted to the intensive care unit. Of the 183 vaccinated patients, 78.1% (n = 143) were discharged from the emergency department, 16.4% (n = 30) were admitted to the service, and 5.5% (n = 10) were admitted to the intensive care unit. In the vaccinated patient group, both the service admission rate and the intensive care hospitalization rate were found to be significantly lower than the non-vaccinated patient group ( < 0.05). Thoracic tomography findings of 32.9% (n = 103) of 313 unvaccinated patients were reported as CORADS 1-2-3, and thoracic tomography of the remaining 210 patients was reported as CORADS 4-5. The number of patients whose thorax tomography report was CORADS 4-5 was found to be significantly higher in the unvaccinated group than in the vaccinated group ( < 0.05).

Conclusion

In our study, it was found that vaccination significantly reduced hospitalization in COVID-19 patients. Although the mean age was higher in the vaccinated patient group, both the service admission rate and the intensive care admission rate were found to be lower.

Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975319329241010070145
2024-10-15
2026-01-02
Loading full text...

Full text loading...

References

  1. GümüşH. EratT. Öztürkİ. DemirA. KoyuncuI. Oxidative stress and decreased Nrf2 level in pediatric patients with COVID‐19.J. Med. Virol.20229452259226410.1002/jmv.2764035128704
    [Google Scholar]
  2. SachsJ.D. KarimS.S.A. AkninL. The lancet commission on lessons for the future from the COVID-19 pandemic.Lancet2022400103591224128010.1016/S0140‑6736(22)01585‑936115368
    [Google Scholar]
  3. Uptodate.comUpToDate: Trusted, evidence-based solutions for modern healthcare.2022Available From: https://www.uptodate.com
  4. GuanW. NiZ. HuY. Clinical characteristics of coronavirus disease 2019 in China.N. Engl. J. Med.2020382181708172010.1056/NEJMoa200203232109013
    [Google Scholar]
  5. PlotkinS.A. OrensteinW.A. OffitP.A. Vaccines.PhiladelphiaSaunders/Elsevier20081736
    [Google Scholar]
  6. HelpsC LeaskJ BarclayL CarterS. Understanding nonvaccinating parents’ views to inform and improve clinical encounters: A qualitative study in an Australian community.BMJ Open201995026299
    [Google Scholar]
  7. LiuH. ChenS. LiuM. NieH. LuH. Comorbid chronic diseasesare strongly correlated with disease severity among COVID-19 patients: A systematic review and Meta-Analysis.Aging Dis.2020113668678
    [Google Scholar]
  8. BadenL.R. El SahlyH.M. EssinkB. KotloffK. FreyS. NovakR. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine.N. Engl. J. Med.20213845403416
    [Google Scholar]
  9. DaganN. BardaN. KeptenE. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting.N. Engl. J. Med.2021384151412142310.1056/NEJMoa210176533626250
    [Google Scholar]
  10. HaasE.J. AnguloF.J. McLaughlinJ.M. AnisE. SingerS.R. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data.Lancet20213971028718191829
    [Google Scholar]
  11. GünalÖ. TüreE. BayburtluM. Evaluation of patients diagnosed with COVID-19 in terms of risk factors.Mikrobiyol. Bul.202054457558210.5578/mb.69811
    [Google Scholar]
  12. GedikM.S. HakkoymazH. BasanN. Evaluation of patients diagnosed with COVID-19.Van Sağlık Bilimleri Dergisi20201341928
    [Google Scholar]
  13. ThomasS.J. MoreiraE.D.Jr KitchinN. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months.N. Engl. J. Med.2021385191761177310.1056/NEJMoa211034534525277
    [Google Scholar]
  14. BeheraP. SinghA.K. SubbaS.H. Effectiveness of COVID-19 vaccine (covaxin) against breakthrough SARS-CoV-2 infection in India.Hum. Vaccin. Immunother.2022181203445610.1080/21645515.2022.203445635321625
    [Google Scholar]
  15. HalimM. HalimA. TjhinY. COVID-19 vaccination efficacy and safety literature review.J Immunol Allergy20213111010.37191/Mapsci‑2582‑4333‑3(1)‑05833613795
    [Google Scholar]
  16. HeathP.T. GalizaE.P. BaxterD.N. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine.N. Engl. J. Med.2021385131172118310.1056/NEJMoa210765934192426
    [Google Scholar]
  17. PolackF.P. ThomasS.J. KitchinN. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.N. Engl. J. Med.2020383272603261510.1056/NEJMoa203457733301246
    [Google Scholar]
/content/journals/covid/10.2174/0126667975319329241010070145
Loading
/content/journals/covid/10.2174/0126667975319329241010070145
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test